Data obtained in Eμ-Myc mouse lymphomas treated with everolimus clearly show that the lack of TP53 is a mechanism of primary resistance to the rapalog [24], indicating the importance of a TP53-mediated component in the mechanism of action of this class of compounds in lymphomas. This evidence concerns the gene TP53 and lymphoma.